Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis
- PMID: 18769381
- PMCID: PMC3971053
- DOI: 10.1038/jp.2008.132
Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis
Erratum in
- J Perinatol. 2009 Jul;29(7):527
Abstract
Prevention of neonatal infection-related mortality represents a significant global challenge particularly in the vulnerable premature population. The increased risk of death from sepsis is likely due to the specific immune deficits found in the neonate as compared to the adult. Stimulation of the neonatal immune system to prevent and/or treat infection has been attempted in the past largely without success. In this review, we identify some of the known deficits in the neonatal immune system and their clinical impact, summarize previous attempts at immunomodulation and the outcomes of these interventions, and discuss the potential of novel immunomodulatory therapies to improve neonatal sepsis outcome.
Figures
References
-
- Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? Where? Why? Lancet. 2005 Mar 5–11;365(9462):891–900. - PubMed
-
- Marodi L. Innate cellular immune responses in newborns. Clin Immunol. 2006 Feb-Mar;118(2–3):137–44. - PubMed
-
- Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 Apr 17;348(16):1546–54. - PubMed
-
- Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. 2004 Jan;113(1 Pt 1):7–17. - PubMed
-
- Martinot A, Leclerc F, Cremer R, Leteurtre S, Fourier C, Hue V. Sepsis in neonates and children: definitions, epidemiology, and outcome. Pediatr Emerg Care. 1997 Aug;13(4):277–81. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
